Condition 1: hip osteoarthritis. Condition 2: Autologous stem cell. Condition 3: Osteoarthritis of knee. Condition 4: joint pain. Condition 5: Unspecified donor stem cell. Condition 6: Complications of injection. Osteoarthritis of hip Autologous donor, stem cells Osteoarthritis of knee Pain in joint Unspecified donor, stem cells Complications following infusion, transfusion and therapeutic injection
Conditions
Interventions
Intervention 1: Intervention group: Intra-articular injection of placental-derived stem cells in the amount of 15 million cells (2 cc). Intervention 2: Intervention group: Intra-articular injection of
Sponsors
Vira cell company
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: Patient with grade II/III hip osteoarthritis. Lack of response to long-term treatment such as NSAIDs and physiotherapy Consent documented in the consent form. No prior therapeutic interventions, including intra-articular hyaluronic acid or corticosteroid injections, or arthroscopy on the target hip within the past three months. No hip joint pain due to other conditions, such as sacroiliac joint involvement, facet joint issues, pain from lumbar radiculopathy, trochanteric bursitis, or ischial bursitis. No rheumatic joint diseases, pelvic fracture, inguinal or femoral hernia, or presence of lymphadenopathy. No active or suspected infection in the target hip. No HIV, HBV, HCV, or Syphilis infection. No pregnancy or breastfeeding. No history of any cancer, autoimmune disease, or any uncontrolled medical condition.
Exclusion criteria
Exclusion criteria: Having any therapeutic intervention, including intra-articular hyaluronic acid or corticosteroid injection, or arthroscopy on the target hip within the past three months. Having hip joint pain due to other conditions, such as sacroiliac joint involvement, facet joint issues, pain from lumbar radiculopathy, trochanteric bursitis, or ischial bursitis. Having rheumatic joint diseases, fracture in the pelvis, inguinal and femoral hernia, or the presence of lymphadenopathy. Any active or suspected infection in the target hip. Infection with HIV, HBV, HCV, or Syphilis. Pregnancy and breastfeeding. Having any history of cancer or autoimmune disease, or any uncontrolled medical condition
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Achieving an effective and safe treatment for patients with grade II/III hip osteoarthritis. Timepoint: 3 months after injection. Method of measurement: Questionnaire. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactFatemeh Daliri
Bagheiat-allah University of Medical Sciences
Outcome results
None listed